BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

Migraine drug marks Biohaven’s first FDA approval Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval....
BioCentury | Feb 6, 2020
Product Development

2019-nCoV diagnostics ramp up in China, globally

Companies and government organizations have started large-scale deployment of diagnostics to diagnose and screen for 2019-nCoV. If secondary transmission of the virus occurs on a large scale outside China, diagnostics will be essential for effective...
BC Extra | May 13, 2019
Financial News

MGI Tech raises $200M for high throughput gene sequencers

Sequencing technology company MGI Tech raised over $200 million in an undisclosed financing backed by CITIC Goldstone Capital, Green Pine Capital Partners and Orient Securities Capital Investment. MGI Tech Co. Ltd. said it plans to...
BioCentury | Dec 7, 2018
Finance

Taking Tesaro

While the $5.1 billion takeout price for Tesaro Inc. (NASDAQ:TSRO) is a far cry from its $9.8 billion peak valuation, investors who spoke with BioCentury see the final price tag as a fair value. GlaxoSmithKline...
BC Week In Review | Dec 7, 2018
Company News

GSK gains Zejula, immuno-oncology portfolio in $5.1B Tesaro takeout

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal...
BC Extra | Dec 4, 2018
Company News

GSK gains Zejula, immuno-oncology pipeline in $5.1B Tesaro acquisition

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal...
BioCentury | Jan 9, 2018
Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
BC Week In Review | Oct 27, 2014
Clinical News

Breast Cancer Index regulatory update

BioMerieux's Biotheranostics Inc. company said CMS posted a positive coverage and reimbursement policy for the Breast Cancer Index to determine the risk of early and late recurrence and benefit from extended endocrine therapy in patients...
BC Week In Review | Oct 13, 2014
Clinical News

Akynzeo netupitant/palonosetron regulatory update

FDA approved Akynzeo netupitant/palonosetron from Helsinn to treat nausea and vomiting in patients undergoing cancer chemotherapy. The product is a fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) substance P receptor antagonist, and...
BC Extra | Oct 11, 2014
Company News

FDA approves Helsinn's Akynzeo combo for CINV

FDA approved Akynzeo netupitant/palonosetron from Helsinn Healthcare S.A. (Lugano, Switzerland) to treat chemotherapy-induced nausea and vomiting (CINV). Akynzeo, previously known as NEPA , is a fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) Substance...
Items per page:
1 - 10 of 685
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

Migraine drug marks Biohaven’s first FDA approval Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval....
BioCentury | Feb 6, 2020
Product Development

2019-nCoV diagnostics ramp up in China, globally

Companies and government organizations have started large-scale deployment of diagnostics to diagnose and screen for 2019-nCoV. If secondary transmission of the virus occurs on a large scale outside China, diagnostics will be essential for effective...
BC Extra | May 13, 2019
Financial News

MGI Tech raises $200M for high throughput gene sequencers

Sequencing technology company MGI Tech raised over $200 million in an undisclosed financing backed by CITIC Goldstone Capital, Green Pine Capital Partners and Orient Securities Capital Investment. MGI Tech Co. Ltd. said it plans to...
BioCentury | Dec 7, 2018
Finance

Taking Tesaro

While the $5.1 billion takeout price for Tesaro Inc. (NASDAQ:TSRO) is a far cry from its $9.8 billion peak valuation, investors who spoke with BioCentury see the final price tag as a fair value. GlaxoSmithKline...
BC Week In Review | Dec 7, 2018
Company News

GSK gains Zejula, immuno-oncology portfolio in $5.1B Tesaro takeout

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal...
BC Extra | Dec 4, 2018
Company News

GSK gains Zejula, immuno-oncology pipeline in $5.1B Tesaro acquisition

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal...
BioCentury | Jan 9, 2018
Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
BC Week In Review | Oct 27, 2014
Clinical News

Breast Cancer Index regulatory update

BioMerieux's Biotheranostics Inc. company said CMS posted a positive coverage and reimbursement policy for the Breast Cancer Index to determine the risk of early and late recurrence and benefit from extended endocrine therapy in patients...
BC Week In Review | Oct 13, 2014
Clinical News

Akynzeo netupitant/palonosetron regulatory update

FDA approved Akynzeo netupitant/palonosetron from Helsinn to treat nausea and vomiting in patients undergoing cancer chemotherapy. The product is a fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) substance P receptor antagonist, and...
BC Extra | Oct 11, 2014
Company News

FDA approves Helsinn's Akynzeo combo for CINV

FDA approved Akynzeo netupitant/palonosetron from Helsinn Healthcare S.A. (Lugano, Switzerland) to treat chemotherapy-induced nausea and vomiting (CINV). Akynzeo, previously known as NEPA , is a fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) Substance...
Items per page:
1 - 10 of 685